Rhodotorula mucilaginosa DM2025 ameliorates obesity through cholesterol binding and the gut mycobiome–BAT PPARγ/UCP1 axis
4 affiliations
- 1Department of Pathogen Biology and Microecology, College of Basic Medical Sciences, Dalian Medical University, Dalian, PR China
- 2Department of Blood Transfusion, Xi'an Daxing Hospital, Xi'an, PR China
- 3The First Affiliated Hospital, Dalian Medical University, Dalian, PR China
- 4Department of Biotechnology, College of Basic Medical Sciences, Dalian Medical University, Dalian, PR China
Abstract
Obesity is a major global health challenge, necessitating safe and effective therapies. Although probiotics are promising for obesity management, research has focused on bacteria, leaving non-Saccharomyces yeasts underexplored. Here, we investigated the anti‑obesity mechanisms of Rhodotorula mucilaginosa DM2025, isolated from the healthy murine gut. To test whether benefits depend on viable cells, high‑fat diet‑fed mice received either live yeast or its cell‑free supernatant, followed by integrated physiological, genomic, and metabolomic analyzes. Live yeast, but not supernatant, significantly reduced body weight gain, improved serum lipids, and was associated with activation of brown adipose tissue thermogenesis (upregulated PPARγ, PGC1α, UCP1). Though the supernatant lowered total cholesterol, it failed to affect weight or thermogenic genes, indicating cholesterol‑lowering and weight reduction are distinct processes. Live cells were enriched in propionate, indole, and carotenoid‑related metabolites, with genomic support for their biosynthesis. Live yeast reshaped the gut mycobiome, promoting Basidiomycota/Rhodotorula dominance; this fungal restructuring was absent in HFD controls. These findings suggest that R. mucilaginosa DM2025 anti‑obesity efficacy relies on the continuous metabolic activity of live cells, producing thermogenesis‑associated metabolites that may contribute to BAT activation. Additionally, physical cholesterol binding to the yeast cell surface provides a complementary cholesterol‑reduction mechanism. Thus, R. mucilaginosa DM2025 represents a promising live probiotic candidate for obesity intervention.
Related
- Dietary glucoraphenin ameliorates obesity and steatotic liver disease associated with gut dysbiosis induced by a Western diet in mice
- Akkermansia muciniphila Ameliorates Midlife Obesity-Induced Cognitive Impairment via the Microbiota-Metabolism-Neuroinflammation Axis
- Male mice are more susceptible than females to obesity-induced muscle atrophy when fed a high-fat, high-cholesterol diet.
- Integrated metabolic and process engineering of Rhodotorula toruloides for light-driven hydrocarbon production
- Mendelian randomization of gut microbiota and exploratory testing of preventive effect of commercial Rothia mucilaginosa in constipated mice
BibTeX
@article{jing2026rhodotorula,
title = {{Rhodotorula mucilaginosa DM2025 ameliorates obesity through cholesterol binding and the gut mycobiome–BAT PPARγ/UCP1 axis}},
author = {Yikang Jing and Yinghan Xiang and Oumarou Chaibou Zafir and Qiqi Sun and Bingwang Chen and Xinran Cao and Jie Hou and Huajun Li},
journal = {Gut Microbes},
year = {2026},
month = nov,
doi = {10.1080/19490976.2026.2760059},
url = {https://doi.org/10.1080/19490976.2026.2760059},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Rhodotorula mucilaginosa DM2025 ameliorates obesity through cholesterol binding and the gut mycobiome–BAT PPARγ/UCP1 axis
AU - Yikang Jing
AU - Yinghan Xiang
AU - Oumarou Chaibou Zafir
AU - Qiqi Sun
AU - Bingwang Chen
AU - Xinran Cao
AU - Jie Hou
AU - Huajun Li
PY - 2026
DA - 2026/11/10
JO - Gut Microbes
DO - 10.1080/19490976.2026.2760059
UR - https://doi.org/10.1080/19490976.2026.2760059
AB - Obesity is a major global health challenge, necessitating safe and effective therapies. Although probiotics are promising for obesity management, research has focused on bacteria, leaving non-Saccharomyces yeasts underexplored. Here, we investigated the anti‑obesity mechanisms of Rhodotorula mucilaginosa DM2025, isolated from the healthy murine gut. To test whether benefits depend on viable cells, high‑fat diet‑fed mice received either live yeast or its cell‑free supernatant, followed by integrated physiological, genomic, and metabolomic analyzes. Live yeast, but not supernatant, significantly reduced body weight gain, improved serum lipids, and was associated with activation of brown adipose tissue thermogenesis (upregulated PPARγ, PGC1α, UCP1). Though the supernatant lowered total cholesterol, it failed to affect weight or thermogenic genes, indicating cholesterol‑lowering and weight reduction are distinct processes. Live cells were enriched in propionate, indole, and carotenoid‑related metabolites, with genomic support for their biosynthesis. Live yeast reshaped the gut mycobiome, promoting Basidiomycota/Rhodotorula dominance; this fungal restructuring was absent in HFD controls. These findings suggest that R. mucilaginosa DM2025 anti‑obesity efficacy relies on the continuous metabolic activity of live cells, producing thermogenesis‑associated metabolites that may contribute to BAT activation. Additionally, physical cholesterol binding to the yeast cell surface provides a complementary cholesterol‑reduction mechanism. Thus, R. mucilaginosa DM2025 represents a promising live probiotic candidate for obesity intervention.
SN - 1949-0976
SN - 1949-0984
ER -